Amgen, Inc. and Bioeq/Formycon have each moved their biosimilar Stelara (ustekinumab) candidates into Phase III clinical studies, representing a significant step in the race to develop one of the most lucrative ‘next wave’ biosimilar opportunities.
An update to the clinicaltrials.gov website reveals Amgen’s study will evaluate the efficacy, safety, and immunogenicity of the US biotech’s...






